Evidence map›Paper›PMID 39179795›Full record

ArticleCommunications biology2024

PGRMC2 and HLA-G regulate immune homeostasis in a microphysiological model of human maternal-fetal membrane interface.

Ryan C V Lintao, Lauren S Richardson, Ananth Kumar Kammala, Jenieve Chapa, Dianne Aster Yunque-Yap, Kamil Khanipov, George Golovko, Leslie Michelle M Dalmacio, Ramkumar Menon

Abstract read
In one paragraph

Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. UterineCancers · 2025
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ryan C V LintaoDivision of Basic Science and Translational Research, Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, TX, USA.ORCID 0000-0001-7192-2377
Lauren S RichardsonDivision of Basic Science and Translational Research, Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, TX, USA.ORCID 0000-0001-8392-2833
Ananth Kumar KammalaDivision of Basic Science and Translational Research, Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, TX, USA.
Jenieve ChapaDivision of Basic Science and Translational Research, Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, TX, USA.
Dianne Aster Yunque-YapDepartment of Pharmacology and Toxicology, The University of Texas Medical Branch at Galveston, Galveston, TX, USA.
Kamil KhanipovDepartment of Pharmacology and Toxicology, The University of Texas Medical Branch at Galveston, Galveston, TX, USA.ORCID 0000-0002-3881-737X
George GolovkoDepartment of Pharmacology and Toxicology, The University of Texas Medical Branch at Galveston, Galveston, TX, USA.ORCID 0000-0003-4609-2767
Leslie Michelle M DalmacioDepartment of Biochemistry and Molecular Biology, College of Medicine, University of the Philippines Manila, Manila, Philippines.
Ramkumar MenonDivision of Basic Science and Translational Research, Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, TX, USA. ra2menon@utmb.edu.ORCID 0000-0001-9213-6105

Funding

Developing extracellular vesicle based therapeutics against pre-term birth through the use of maternal-fetal interface on a chipUH3TR003283 · NCATS · TEXAS ENGINEERING EXPERIMENT STATION · PI HAN, ARUM, MENON, RAMKUMAR · 2023 to 2025
$2.3M
Developing extracellular vesicle based therapeutics against pre-term birth through the use of maternal-fetal interface on a chipUG3TR003283 · NCATS · TEXAS ENGINEERING EXPERIMENT STATION · PI HAN, ARUM, MENON, RAMKUMAR · 2020 to 2021
$1.5M
3-D biofabricated feto-maternal interface tissue model to determine drug efficacy during pregnancy to reduce the risk of preterm birthUH2TR004117 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI HAN, ARUM, MENON, RAMKUMAR · 2022 to 2023
$842k
3-D biofabricated feto-maternal interface tissue model to determine drug efficacy during pregnancy to reduce the risk of preterm birthUH3TR004117 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Arum Han, RAMKUMAR MENON · 2024 to 2026
$702k
NCATS NIH HHS UG3 TR003283NCATS NIH HHS UH2 TR004117NCATS NIH HHS UH3 TR003283NCATS NIH HHS UH3 TR004117U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS) UH2TR004117-01U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS) UH3TR003283-03
6 · The paper itself

Abstract

Chorion trophoblasts (CTCs) and immune cell-enriched decidua (DECs) comprise the maternal-fetal membrane interface called the chorio-decidual interface (CDi) which constantly gets exposed to maternal stressors without leading to labor activation. This study explored how CTCs act as a barrier at CDi. The roles of human leukocyte antigen (HLA)-G and progesterone receptor membrane component 2 (PGRMC2) in mediating immune homeostasis were also investigated. The CDi was recreated in a two-chamber microfluidic device (CDi-on-chip) with an outer chamber of primary DECs and immune cell line-derived innate immune cells and an inner chamber of wild-type or PGRMC2 or HLA-G knockout immortalized CTCs. To mimic maternal insults, DECs were treated with lipopolysaccharide, poly(I:C), or oxidative stress inducer cigarette smoke extract. Expression levels of inflammation and immunity genes via targeted RNA sequencing, production of soluble mediators, and immune cell migration into CTCs were determined. In CDi-on-chip, decidua and immune cells became inflammatory in response to insults while CTCs were refractory, highlighting their barrier function. HLA-G and PGRMC2 are found to be vital to immune homeostasis at the CDi, with PGRMC2 serving as an upstream regulator of inflammation, HLA-G expression, and mesenchymal-epithelial transition, and HLA-G serving as a frontline immunomodulatory molecule, thus preventing fetal membrane compromise.

Indexed as

HLA-G AntigensHomeostasisReceptors, ProgesteroneChorionDeciduaExtraembryonic MembranesFemaleHumansMembrane ProteinsPregnancyTrophoblastsHLA-G AntigensMembrane ProteinsPGRMC2 protein, humanReceptors, Progesterone

Identifiers

PMID39179795
PMCPMC11344061

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.